In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa | Zendy

Tomefa E. Asempa | Zendy; David P. Nicolau | Zendy; Joseph L. Kuti | Zendy

Open Access

In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa

Author(s) -

Tomefa E. Asempa,

David P. Nicolau,

Joseph L. Kuti

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00997-19

Subject(s) - colistin , imipenem , pseudomonas aeruginosa , amikacin , microbiology and biotechnology , biology , antibacterial agent , in vitro , carbapenem , antibiotics , bacteria , antibiotic resistance , biochemistry , genetics

Relebactam is a novel class A/C β-lactamase inhibitor that restores imipenemin vitro activity against multidrug-resistant and carbapenem-nonsusceptiblePseudomonas aeruginosa . Time-kill analyses were performed to evaluate the potential role of imipenem-relebactam in combination with amikacin or colistin againstP. aeruginosa . Ten clinicalP. aeruginosa isolates (9 imipenem nonsusceptible) with imipenem-relebactam MICs ranging from 1/4 to 8/4 μg/ml were included.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research